Jan 09, 2020: Novartis, a leader in immuno-dermatology, announced mechanistic study results showing ligelizumab is more efficient at inhibiting the major pathogenic IgE/FcεRI pathway in the chronic spontaneous urticaria (CSU), than current therapy. olair® (omalizumab).
Ligelizumab can bind to IgE with an 88-fold higher resemblance than Xolair. The data demonstrate ligelizumab and Xolair recognize and bind differently to IgE, with ligelizumab resulting in a considerably enhanced blockade of IgE/FcεRI signaling.
The data, published in The New England Journal of Medicine, shows an average complete response rate of 42% for 240 mg and 72 mg of ligelizumab at Week 12, compared with 26% for those taking 300 mg of Xolair. https://www.novartis.com/news/media-releases/novartis-ligelizumab-qge031-more-effective-xolair-inhibiting-immunoglobulin-e-pathway-responsible-chronic-spontaneous-urticaria
